New SCLC Biomarkers Fuel Precision Medicine Advances

On October 11, 2024, a new research paper was released in Oncotarget’s Volume 15, entitled “Relationship between the expressions of DLL3, ASC1, TTF-1, and Ki-67: First steps of precision medicine at SCLC”

This study, conducted by researchers from the Federal University of Ceará in Brazil and partner institutions in Brazil, Argentina, and Spain, reports significant discoveries on small cell lung cancer (SCLC), one of the most aggressifcancerve kinds of lung cancer with few treatment options. The study demonstrates how distinct biomarkers in SCLC tumors could lead to more tailored and targeted therapy for these individuals.

SCLC accounts for approximately 15% of all lung cancer cases and is characterized by its fast spread and resistance to various treatments. Currently, the five-year survival rate for SCLC patients is less than 5%. Recent breakthroughs in precision medicine seek to improve these outcomes by recognizing and targeting the distinct characteristics of each patient’s tumor.

Samuel Silva, Juliana C. Sousa, Cleto Nogueira, Raquel Feijo, Francisco Martins Neto, Laura Cardoso Marinho, Guilherme Sousa, Valeria Denninghoff, and Fabio Tavora examined tumor samples from 64 SCLC patients using traditional and digital pathology tools. Their findings showed promising outcomes for two of the biomarkers studied: Delta-like ligand 3 (DLL3) and Thyroid transcription factor-1 (TTF-1).

DLL3 was found in more than 70% of the tumors, indicating its potential as a promising target for therapies such as Tarlatamab. Another significant observation concerned TTF-1 expression; patients with TTF-1-positive tumors had higher survival rates, highlighting its potential as a prognostic marker for refining diagnoses and predicting patient outcomes.

The authors also noted that, “The use of digital pathology software QuPath enhanced the accuracy and depth of analysis, allowing for detailed morphometric analysis and potentially informing more personalized treatment approaches.”

In conclusion, the study implies that clinical trials targeting biomarkers such as DLL3 and TTF-1 could improve SCLC patient outcomes by personalizing treatments to specific biomarker profiles. This study represents a significant advance in precision medicine for SCLC.

For more information: Silva, S., et al. (2024) Relationship between the expressions of DLL3, ASC1, TTF-1 and Ki-67: First steps of precision medicine at SCLC. Oncotarget. doi.org/10.18632/oncotarget.28660.